Breakthrough Biotech Builders: Session with Steve Paul
This discussion would be a private gathering designed to foster high-level dialogue and genuine connections in the area of biotech leadership. We hope that such discussions will provide founders & CEOs of biotech companies an opportunity to engage directly with pioneers in the field, and learn from their experience bringing a drug candidate through a successful development path to the clinic. Our first session will be an in-depth dialogue with Dr. Steve Paul, moderated by Professor William Chin. Bios of Steve and Bill below:
About Steve Paul
Dr. Steve Paul is a distinguished American neuroscientist and pharmaceutical executive with nearly 50 years of experience in neuroscience and CNS drug discovery. He served as the former CEO, President, and Chairman of Karuna Therapeutics (acquired by Bristol Myers Squibb for $14 billion). Before that, he was President of Lilly Research Laboratories and Executive Vice President for Science and Technology at Eli Lilly and Company for 17 years, and Scientific Director at the National Institute of Mental Health (NIMH) for 18 years. Dr. Paul has also co-founded several notable biotech companies, including Sage Therapeutics, Voyager Therapeutics, Seaport Therapeutics, and Rapport Therapeutics. He is currently a Venture Partner at Third Rock Ventures.
About Bill Chin
Dr. William (Bill) Chin is the Bertarelli Professor of Translational Medical Science and Professor of Medicine Emeritus at Harvard Medical School. He previously served as Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer at PhRMA, leading advocacy efforts with the FDA and NIH. Before PhRMA, he was Executive Dean for Research at HMS and Senior Vice President for Discovery Research and Clinical Investigation at Eli Lilly, overseeing over 100 drug candidates. A Harvard-trained endocrinologist, Dr. Chin has a distinguished 25-year career at HMS, including roles as Chief of the Genetics Division at Brigham and Women’s Hospital and a Howard Hughes Medical Institute Investigator. He has advised Singapore for over 40 years on developing its biotechnology innovation ecosystem, serving as an active Board Member of A-STAR. In 2023, he received honorary Singapore citizenship for these contributions. Dr. Chin earned his A.B. from Columbia University and M.D. from Harvard Medical School, and has received numerous awards for research, mentorship, and leadership.
About TINS
Technology Innovation Studio (TINS) is an innovation studio that uses systems dynamics models to accelerate innovation. TINS carries out interest groups based programming and builds communities through curated events and complements this with expert-led concierge and consulting services. TINS has interests in venture creation and in doing syndicated investments in early-stage deep-tech companies.